Par Drugs and Chemicals Ltd
NSE:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.5), the stock would be worth ₹219.64 (137% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.4 | ₹92.75 |
0%
|
| 3-Year Average | 10.5 | ₹219.64 |
+137%
|
| 5-Year Average | 11.4 | ₹237.32 |
+156%
|
| Industry Average | 21.2 | ₹441.55 |
+376%
|
| Country Average | 17.7 | ₹368.49 |
+297%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Par Drugs and Chemicals Ltd
NSE:PAR
|
1.1B INR | 4.4 | 8.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 27.8 |
| Max | 47 834.4 |
Other Multiples
Par Drugs and Chemicals Ltd
Glance View
Par Drugs & Chemicals Ltd. engages in the development and manufacture of Active Pharma Ingredients (API) for the domestic market as well as for exports to international markets. The company is headquartered in Bhavnagar, Gujarat. The company went IPO on 2019-05-16. The firm also produces a range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide and sucralfate USP. The firm owns and operates its manufacturing facilities at Bhavnagar in Gujarat. The company has over four manufacturing blocks at Bhavnagar, which are for different products having a capacity of approximately 9,700 metric tons per annum.
